Proteomics diagnostic tests shift from lab coats to commercial launch

Proteomics International Laboratories has drawn a line under its long research phase and is now marching toward what every listed biotech eventually needs – commercial traction.

In a fresh strategic presentation released this week under the guidance of its new managing director and chief executive officer, David Morris, the Perth-based company outlined a disciplined three-year plan to convert its proteomics science platform into a scalable diagnostics business, with clear priorities around sales growth, reimbursement pathways and operational efficiency.

For smaller life sciences players, that transition can be the toughest hurdle. Great science does not always translate into revenue. Proteomics appears well aware of the challenge and has chosen a capital-light route, leaning on distribution partners rather than on expensive in-house sales infrastructure.

Management says its distributor model should enable earlier acceptance and adoption, lower establishment risk and better capital efficiency than devoting time and effort on running direct or hybrid sales channels.

The company’s portfolio currently centres on four tests. Leading the charge is PromarkerD, a blood test that predicts diabetes-related chronic kidney disease up to four years before symptoms appear.

The potential opportunity is huge, given the soaring global diabetes burden and the high cost of kidney failure once it develops. Proteomics estimates an initial market of about 20,000 annual tests in Australia and 390,000 in the United States.

The company’s next offering, PromarkerEso, is aimed at patients with chronic reflux. The test is designed to help rule out oesophageal adenocarcinoma – throat cancer – by using a straightforward blood sample instead of the prevailing reliance on invasive surveillance endoscopy, which involves sending a camera down the food pipe.

Management has pegged the medium-term market opportunity for the test at 15,000 tests annually in Australia and 240,000 in the US.

Next cab off the rank is Proteomics’ PromarkerEndo diagnostic test, which targets endometriosis – one of the most frustrating conditions in women’s health. Before PromarkerEndo, the condition had a well-known history of delayed diagnosis, often taking many years to confirm.

Proteomics says its test could significantly shorten that pathway, with an estimated potential market of 50,000 annual tests in Australia and 360,000 in the US.

Rounding out its current four-test stable is OxiDx. This oxidative stress testing platform could find a home in specialist medicine, the monitoring of elite athletes and even the equine veterinary market, giving the company another lever outside mainstream human pathology channels.

Notably, the company’s roadmap has been carefully laid out in stages rather than purely speculative. In the first half of FY27, Proteomics plans to appoint an Australian distributor, finalise its assay validations for PromarkerEndo and launch local controlled market releases.

By the second half of FY27, management aims to establish a US distribution network for the balance of its tests and begin its reimbursement submissions in both countries.

In the world of big pharma, a reimbursement submission is essentially a company’s pitch to get its new drug or test paid for. It involves putting together a detailed case for governments or insurers, including clinical results, proof it works and evidence it delivers value for money.

Australia already provides a national reimbursement framework through the Medicare Benefits Schedule (MBS). A listing for Proteomics would be a significant milestone and likely a significant driver of growth.

The company has flagged FY28 as its breakout year, with plans to widen its network, drive stronger uptake of its tests and scale up laboratory capacity. By FY29, the focus shifts to tightening operations, expanding the test portfolio and chasing broader strategic growth opportunities across global markets.

However, the reimbursement angle could be the real prize. In Australia, eventual MBS listing would materially widen patient access. At the same time, in the US, success often comes payer by payer, meaning progress may be slower but potentially highly lucrative once momentum builds.

Proteomics also recently refreshed its board and leadership bench, bringing in executives with deep experience in commercialisation, global pharmaceuticals and international expansion – a clear signal the company is shifting its focus from the lab to the sales front.

Proteomics’ managing director and CEO, David Morris, said the changes mark an important step in positioning Proteomics as a commercial diagnostics company, focused on ensuring clear strategic priorities, a streamlined organisation, and a strengthened financial position.

The company now has four products on deck, a partner-led rollout, an evolving distribution model and the massive US diagnostics market in its sights.

Proteomics now appears to be entering a stage where punters stop asking what the science can do and start asking what the revenue line might look like as the products take off on their own unique trajectories.

Is your ASX-listed company doing something interesting? Contact: mattbirney@bullsnbears.com.au